Innovate UK

EnrichMyCare helps to solve some of the critical problems including delays with communication and care, information sharing and disjointed healthcare provision across health, social care and education. The platform offers opportunities for automating carepathways, remotely monitoring management plans and compliance with exercise and splinting programmes. Our early research suggests that this would help with accelerating care, better patient monitoring and engagement to prevent disabilities from developing and improving the overall care experience whilst also reducing healthcare costs.

Mulder provides blockchain-based, end-to-end traceability for medical devices, enhancing patient safety and manufacturer accountability.

Mulder provides blockchain-based, end-to-end traceability for medical devices, enhancing patient safety and manufacturer accountability.

Kaydiar is an innovative medical device company that specializes in offloading technology, we are committed to innovating superior products for cost-effective wound care, such as orthotic devices, bed mattresses, wheelchair cushions and prosthetic sleeves.

Naitive is a population health company focused on improving patient care through AI-enabled clinical pathways and medical device technology. The company develops software that employs artificial intelligence, clinical data, and digital interventions to enhance the identification, treatment, and coordination of care for chronic diseases. By leveraging advanced computational capabilities, Naitive aims to support clinicians in transforming patient care while simultaneously reducing costs, time, and the failure rates commonly associated with chronic disease management.

Siloton is a medical device manufacturer focused on creating diagnostic imaging devices for ophthalmology. The company specializes in developing advanced portable optical coherence tomography devices designed to address challenges in eye care. Their hand-held sub-surface imaging technology allows for home-based scanning, providing users with the ability to monitor their eye health and contribute to the prevention of avoidable blindness.

SleepCogni is focused on developing innovative sleep aid technology that facilitates a personalized wind-down process to enhance sleep quality. The company's device, activated manually, utilizes sensors worn on the user's index finger to monitor key physiological and behavioral indicators, including heart rate, mental alertness, skin temperature, and movement. By employing cognitive behavioral therapy through biofeedback—delivered via visual, auditory, and tactile cues—SleepCogni aims to help users relearn healthy sleep patterns. This approach is designed to assist individuals in overcoming insomnia and improving their overall sleep cycle, offering a tailored solution to address common sleep challenges.

Occuity Ltd is a company based in Reading, United Kingdom, that focuses on the research, design, and manufacture of non-contact optical instruments for healthcare diagnostics and monitoring. Founded in 2019, it offers a range of handheld devices, including pachymeters, pupillometers, and keratometers, which are utilized in both human and veterinary optometry. These instruments employ light to analyze the eye, facilitating direct measurements that assist optometrists and ophthalmologists in diagnosing and monitoring various health conditions, such as diabetes and Alzheimer's disease. By providing innovative non-contact solutions, Occuity aims to enhance the effectiveness and accessibility of diagnostic and screening technologies in the healthcare sector.

Cortirio specializes in the development of portable brain imaging technology aimed at diagnosing and monitoring traumatic brain injuries, which are a leading cause of death and disability among individuals under 40. The company's innovative portable scanners utilize near-infrared imaging with enhanced spatial resolution to deliver point-of-care medical imaging. This technology enables healthcare providers to access vital information throughout the clinical pathway, facilitating automatic analysis and data transfer. By providing timely and accurate diagnostic capabilities, Cortirio's devices empower clinicians to make quicker decisions, ultimately improving care for patients suffering from brain injuries and strokes.

PulmoBiomed is a developer of innovative sampling technology that offers a non-invasive method for clinicians and researchers to collect biological samples. The company's primary product is a passive fluid aerosol sampler designed to capture exhaled breath condensate and environmental particles, effectively segregating them by size. This technology addresses critical challenges in sample collection, such as preventing contamination and loss, while ensuring the generation of highly reproducible data with digital molecular precision. By focusing on metabolomic profiling and biological agent capture, PulmoBiomed aims to enhance the accuracy and reliability of respiratory diagnostics and research.

Physiomics plc combines systems biology with cutting edge mathematics to develop models that streamline the drug discovery and development process. Virtual Tumour, the company’s lead service, is used to optimise the dosing and scheduling of oncology drugs in pre-clinical and clinical trials. This optimisation improves the efficacy of combinations and streamlines the drug development process.

ZiO Health is a biotechnology company that focuses on transforming laboratory testing through its proprietary pocket-sized technology, which allows for point-of-care diagnostics. By combining advanced biosensor technology with machine learning algorithms, ZiO Health provides real-time testing results tailored to each patient's unique profile. This innovative approach enables users to measure, test, and detect the molecular composition of various substances, facilitating personalized health insights. The company's devices aim to optimize health management and enhance patient outcomes, allowing individuals to conduct quality home diagnostics and take proactive steps in preventing illness.

Kalium Health Ltd is a company focused on improving kidney care through innovative medical technology. Based in Cambridge, United Kingdom, it designs and manufactures a finger-prick blood test specifically for measuring blood potassium concentration. This test aims to facilitate early treatment for patients, reducing the complications and costs associated with traditional testing methods. By leveraging advanced electrolyte sensing technology, Kalium Health provides patients with accurate, real-time data essential for managing cardiorenal diseases. The company’s first product addresses a significant risk in kidney disease, a condition that imposes substantial financial burdens on healthcare systems. With a clear regulatory pathway and a targeted market strategy, Kalium Health is poised to transform patient care and enhance outcomes for millions affected by kidney disease.

SMi Systems is a biomedical research and medical equipment manufacturing organization specializing in the development of advanced diagnostic and discovery tools. Their high-performance diagnostic devices, capable of detecting diseases within the first 24 hours of infection, can simultaneously identify multiple conditions. By automating and enhancing throughput, these tools significantly reduce processing time for patient samples. Additionally, SMi Systems' technology enables scientists to measure critical molecular interactions associated with various diseases, allowing for a deeper understanding of therapeutic mechanisms. This capability supports extensive scientific research and clinical diagnostics across numerous disease areas, facilitating the observation of diverse molecular interactions and the monitoring of drug binding to targets.

SMi Systems is a biomedical research and medical equipment manufacturing organization specializing in the development of advanced diagnostic and discovery tools. Their high-performance diagnostic devices, capable of detecting diseases within the first 24 hours of infection, can simultaneously identify multiple conditions. By automating and enhancing throughput, these tools significantly reduce processing time for patient samples. Additionally, SMi Systems' technology enables scientists to measure critical molecular interactions associated with various diseases, allowing for a deeper understanding of therapeutic mechanisms. This capability supports extensive scientific research and clinical diagnostics across numerous disease areas, facilitating the observation of diverse molecular interactions and the monitoring of drug binding to targets.

Boost Innovations focuses on developing products specifically for women, with a particular emphasis on enhancing comfort and confidence. The company specializes in creating breast prostheses designed to provide both security and usability for users, especially those who have undergone surgery. Their innovative breast forms are crafted to remain secure within post-surgery underwear and are suitable for various activities, including swimming and exercising. By prioritizing breathability and functionality, Boost Innovations aims to meet the unique needs of its customers, ensuring they feel comfortable and confident in their daily lives.

Orthonika Limited, established in 2014 and based in London, United Kingdom, specializes in the development and manufacturing of MenisciKnit, an anatomical meniscus replacement designed to address severe meniscus injuries. These injuries can significantly impair mobility and lead to complications such as osteoarthritis and the need for knee arthroplasty. Current treatment options, including partial meniscectomy and allograft transplantation, often fall short, leaving a significant unmet need in the market. MenisciKnit employs a unique fiber-reinforced material structure that closely mimics the natural meniscus, aiming to restore proper knee biomechanics. This innovative approach not only provides a solution for those with severe meniscus damage but also supports patients in resuming active lifestyles and offers a comprehensive alternative to traditional knee-related treatments.

Calla Lily Clinical Care is a women’s health-focused B-Corp that has created the proprietary Callavid® platform for intravaginal drug delivery. The company targets fertility and pregnancy with its innovative drug-device combination product aimed at preventing miscarriages and providing support during the luteal phase of In Vitro Fertilization (IVF). Additionally, Callavid® is designed to deliver live biotherapeutics to address recurrent Bacterial Vaginosis, thereby reducing antibiotic use and mitigating the spread of antimicrobial resistance. Other applications include hormone replacement therapy for menopause and the Lilyvid™ device, which facilitates advanced medical sample collection for biomarker-based diagnostics related to endometriosis and various other health conditions. The technology behind these devices has been recognized as a TIME Magazine Best Invention of the Year.

PatientMpower specializes in remote monitoring solutions aimed at patients with chronic diseases, particularly those with respiratory conditions. The company develops applications that integrate with devices such as spirometers and pulse oximeters, allowing patients to conduct measurements at home. These devices connect to a smartphone application, which transmits real-time data to healthcare providers. This integration supports healthcare professionals in delivering high-quality care and enhances patient outcomes by facilitating continuous monitoring. Additionally, the data collected contributes to research efforts aimed at improving treatment options for chronic conditions.

Silveray develop affordable large-area direct conversion detectors for the X-ray imaging market.

ProtonDx is a diagnostic platform specializing in molecular testing services that focus on detecting and differentiating multiple pathogens from patient samples. The company develops point-of-care diagnostic test devices that aid healthcare professionals in diagnosing infectious diseases using innovative handheld technology. By integrating advanced microchip technology with molecular biology and machine learning, ProtonDx offers rapid, sensitive, and specific testing solutions that can be deployed in hospital settings. This capability allows healthcare organizations to efficiently manage clinical cases and monitor infectious disease outbreaks in real-time. Customer inquiries can be addressed through contact forms and email.

At OCUWELL, we're revolutionising eye care with our innovative, cloud-based solutions designed to make quality eye care accessible and affordable for everyone, everywhere. Our flagship product is a portable corneal topographer addressing the global need for essential diagnostic tools in treating corneal disorders, which affect over 2.2 billion people. With a unique B2B and SaaS business model, backed by 25 years of leading scientific research, we're on track to transform the delivery of eye care worldwide.

OKKO Health specializes in developing home-monitoring applications for eye health, utilizing advanced algorithms that integrate vision science, computer science, and game technology. Their software allows patients at high risk for eye diseases to monitor their eyesight from home, promoting early detection and personalized care. By enabling self-assessment between clinical appointments, OKKO Health aims to enhance patient engagement and streamline appointment scheduling. The company’s innovative approach combines scientific research with practical applications in clinical practice and drug development, providing a reliable method for measuring vision and predicting potential deterioration in eye health.

For expectant & new parents, Anya is the best tool to support you through your early parenthood & breastfeeding journey. Anya is here to support you with credible & expert guidance every step of the way, using unique LatchAid™ 3D interactive breastfeeding animations, the Anya virtual supporter answering your questions 24/7, real-life experts ready to help, & close-knit communities where you can connect with other parents. Whether you have questions about pregnancy, birth, latching, combination feeding, pumping, cluster feeding, milk supply, reflux, sleep, nappies, going back to work or more, Anya offers peer-to-peer support & professional assistance. Giving you confidence to be the parent you want to be, so you don’t feel exhausted, frustrated or in pain. Anya is an easy-to-use app for parenting & breastfeeding support, including: LatchAid™ 3D breastfeeding tool: * Interactive animations to help you learn breastfeeding skills visually. * Camera responds to your touch & shows you how to position your baby at the breast, using your desired angles & X-ray mode to see inside the baby’s mouth. * Demonstrating different breastfeeding positions, accompanied by audio & subtitles. * Personalise breast sizes & skin tones to represent you & your baby. Anya AI virtual supporter: support anytime, anywhere: * Providing parents with personalised support & companionship, 24/7, worldwide. * Answers all your questions regarding infant feeding, baby care, pregnancy, & parental health. * Our knowledge base is constantly evolving based on hundreds of questions from parents like you worldwide. * Access 1-1 support from our real-life experts on anything about mother & baby wellbeing, or parental health to get credible, evidence-based answers. Peer support communities: * It takes a village to raise a child. Connect with other parents to share knowledge & experience, to create lasting friendships & access help through in-app virtual chat groups. Parenting & breastfeeding support: * Access the knowledge base of top experts with internationally-recognised qualifications. * Tailored insight page to your baby's age & stage. * Explore articles, videos & FAQs related to your current stage 24/7. * Join in with our in-app events or watch them back to suit you. Interactive expert webinars: * Connect with qualified infant feeding, baby care, & parental health experts in weekly webinars & drop-in Q&A sessions. * Get professional advice in a supportive environment, all from the comfort of your own home. Why download Anya? * Anya is the only breastfeeding & early parenthood support app powered by empathy & innovation. * Downloaded & trusted by 1000s of parents around the world. * You can learn to breastfeed confidently with our help. Solves a problem 90% of new mothers face, due to pain, lack of support & faltering confidence with breastfeeding. * Recommended by the NHS in the UK, so you know it’s high quality. * An innovative & complementary solution to traditional breastfeeding support that offers AI virtual supporter, 1-to-1 specialist support, & a peer community to empower parents to give their child the best start in life. * We build the confidence of mothers to achieve their infant feeding goals with animations, peer community, 24/7 specialist support & personalised AI companion. As soon as you become a parent, you have questions, lots of them! Anya and LatchAid™ were developed by specialists who work with parents every day to help them reach their parenting & breastfeeding goals. Many mothers of newborn babies give up breastfeeding less than three months after birth, due to physical pain, frustration & anxiety. We are here to help support you with empathy & companionship and to answer all of your 3am worries. We believe that every parent deserves the support & empowerment to give their child the best start in life. Together we nurture.

Vamstar operates a B2B healthcare supply chain platform that addresses inefficiencies in the sourcing and procurement processes for medical devices and pharmaceuticals. By utilizing advanced data automation technologies such as machine learning, Vamstar aggregates demand from millions of sources, creating a comprehensive marketplace that connects buyers, including hospitals and health systems, with a vast network of suppliers. The platform provides real-time analytics and valuable tools for search and bid development, allowing users to quickly identify suitable opportunities and finalize transactions. With access to a significant volume of global demand and millions of contracts, Vamstar simplifies the procurement process, helping healthcare organizations reduce costs and improve access to essential products and services. The company is dedicated to building a digital marketplace that fosters innovation in healthcare and is supported by leading investors in the field.

SleepCogni is focused on developing innovative sleep aid technology that facilitates a personalized wind-down process to enhance sleep quality. The company's device, activated manually, utilizes sensors worn on the user's index finger to monitor key physiological and behavioral indicators, including heart rate, mental alertness, skin temperature, and movement. By employing cognitive behavioral therapy through biofeedback—delivered via visual, auditory, and tactile cues—SleepCogni aims to help users relearn healthy sleep patterns. This approach is designed to assist individuals in overcoming insomnia and improving their overall sleep cycle, offering a tailored solution to address common sleep challenges.

CryoLogyx is an early-stage biotechnology company focused on advancing cell cryopreservation technology to enhance drug discovery processes. By employing innovative methods that utilize cryoprotectants, CryoLogyx transforms the freezing, storage, and transportation of cells. This proprietary technology ensures the delivery of viable, ready-to-use cells and cell therapies, allowing healthcare researchers to access these resources in the desired format. The company's approach aims to improve the efficiency and effectiveness of cell-based research in the fields of medicine discovery, diagnostics, and cell therapy.

Bea Fertility is a monthly subscription program that provides users with at-home fertility treatment and ovulation tracking. The kits offered by Bea Fertility include an intracervical insemination device, as well as pregnancy tests, fertility trackers, and sperm donation pots. Bea Fertility democratizes effective and affordable fertility treatment for individuals and couples who are having difficulty conceiving.

Vamstar operates a B2B healthcare supply chain platform that addresses inefficiencies in the sourcing and procurement processes for medical devices and pharmaceuticals. By utilizing advanced data automation technologies such as machine learning, Vamstar aggregates demand from millions of sources, creating a comprehensive marketplace that connects buyers, including hospitals and health systems, with a vast network of suppliers. The platform provides real-time analytics and valuable tools for search and bid development, allowing users to quickly identify suitable opportunities and finalize transactions. With access to a significant volume of global demand and millions of contracts, Vamstar simplifies the procurement process, helping healthcare organizations reduce costs and improve access to essential products and services. The company is dedicated to building a digital marketplace that fosters innovation in healthcare and is supported by leading investors in the field.

Ingenion Medical is a medical device company. The Company specializes in creating innovative, clinically relevant, and cost-effective solutions to problems of urinary flow and control.

OKKO Health specializes in developing home-monitoring applications for eye health, utilizing advanced algorithms that integrate vision science, computer science, and game technology. Their software allows patients at high risk for eye diseases to monitor their eyesight from home, promoting early detection and personalized care. By enabling self-assessment between clinical appointments, OKKO Health aims to enhance patient engagement and streamline appointment scheduling. The company’s innovative approach combines scientific research with practical applications in clinical practice and drug development, providing a reliable method for measuring vision and predicting potential deterioration in eye health.

OKKO Health specializes in developing home-monitoring applications for eye health, utilizing advanced algorithms that integrate vision science, computer science, and game technology. Their software allows patients at high risk for eye diseases to monitor their eyesight from home, promoting early detection and personalized care. By enabling self-assessment between clinical appointments, OKKO Health aims to enhance patient engagement and streamline appointment scheduling. The company’s innovative approach combines scientific research with practical applications in clinical practice and drug development, providing a reliable method for measuring vision and predicting potential deterioration in eye health.

OKKO Health specializes in developing home-monitoring applications for eye health, utilizing advanced algorithms that integrate vision science, computer science, and game technology. Their software allows patients at high risk for eye diseases to monitor their eyesight from home, promoting early detection and personalized care. By enabling self-assessment between clinical appointments, OKKO Health aims to enhance patient engagement and streamline appointment scheduling. The company’s innovative approach combines scientific research with practical applications in clinical practice and drug development, providing a reliable method for measuring vision and predicting potential deterioration in eye health.

Vitrue Health focuses on developing digital technology to address musculoskeletal issues through accurate measurement and analysis. Their flagship product, VIDA, is a comprehensive service aimed at reducing problems such as back and neck pain among desk workers by ensuring compliance with ergonomic standards for remote, office, and hybrid environments. Utilizing advanced AI, VIDA assesses workspace quality and empowers employees with knowledge to improve their environments, thereby enhancing their overall well-being. Additionally, Vitrue's EVVA technology employs depth sensors for clinical-grade assessments in orthopaedics and injury prevention, offering precise evaluations of functional movements throughout rehabilitation. By leveraging computer vision and biomechanics, Vitrue Health not only collects and analyzes health data but also provides actionable insights to both clinicians and patients, promoting early detection of issues and informed decision-making in treatment plans. Their mission is to transform musculoskeletal healthcare and significantly reduce pain for millions of individuals.

Vamstar operates a B2B healthcare supply chain platform that addresses inefficiencies in the sourcing and procurement processes for medical devices and pharmaceuticals. By utilizing advanced data automation technologies such as machine learning, Vamstar aggregates demand from millions of sources, creating a comprehensive marketplace that connects buyers, including hospitals and health systems, with a vast network of suppliers. The platform provides real-time analytics and valuable tools for search and bid development, allowing users to quickly identify suitable opportunities and finalize transactions. With access to a significant volume of global demand and millions of contracts, Vamstar simplifies the procurement process, helping healthcare organizations reduce costs and improve access to essential products and services. The company is dedicated to building a digital marketplace that fosters innovation in healthcare and is supported by leading investors in the field.

Arete Medical Technologies is a startup focused on developing medical devices and software aimed at precision management of chronic diseases, with an initial emphasis on asthma and chronic obstructive pulmonary disease (COPD). The company creates digital therapeutic devices that allow for personalized and preventative care in chronic respiratory conditions. Arete Medical utilizes advanced hardware and software technologies to reduce sensor costs and incorporates artificial intelligence and biomechanical modeling to enhance patient outcomes. This approach aims to support medical practitioners in improving patient care and increasing the efficiency of healthcare systems.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

OKKO Health specializes in developing home-monitoring applications for eye health, utilizing advanced algorithms that integrate vision science, computer science, and game technology. Their software allows patients at high risk for eye diseases to monitor their eyesight from home, promoting early detection and personalized care. By enabling self-assessment between clinical appointments, OKKO Health aims to enhance patient engagement and streamline appointment scheduling. The company’s innovative approach combines scientific research with practical applications in clinical practice and drug development, providing a reliable method for measuring vision and predicting potential deterioration in eye health.

BrainWaveBank has developed a first-in-class wearable electroencephalography (EEG) device to conveniently and non-invasively measure the mechanisms that underpin neurological disorders and therapies. Our platform can securely gather, store and analyse data from many thousands of users, building neurocognitive profiles of individuals and populations or demographic groups. This easy-to-scale and distributable approach will help clinical professionals to transform our understanding of brain health and develop the next generation of treatments. BrainWaveBank was founded in January 2015 and has offices in Belfast , Northern Ireland and Dublin, Ireland.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

MediSieve Ltd. is a medical device company based in London, United Kingdom, focused on developing Magnetic Blood Filtration (MBF) technology to treat blood-borne diseases. Established in 2014, the company has created a blood filtration device that magnetically removes infected blood cells, enabling the treatment of conditions such as malaria, leukemia, and sepsis. The MBF system operates by circulating a patient’s blood through an external loop where targeted magnetic particles bind to disease-relevant targets. The blood then passes through a magnetic filter that captures these particles and bound targets, allowing the unaffected blood to be returned to the patient. MediSieve's innovative approach also aims to enhance the safety and efficacy of existing therapies while expanding the range of treatable diseases. The company operates from the Imperial Incubator in White City, London, where it has specialized laboratory facilities for product development and validation.

Bioinduction specializes in the development of neuromodulation devices aimed at treating chronic pain and various neurological disorders. The company's innovative products include a skull-mounted deep brain stimulation (DBS) platform that offers advanced features such as neural recording and target steering. These enhancements not only streamline surgical procedures but also prioritize patient comfort by improving the device's placement compared to conventional DBS systems. Bioinduction's focus on creating faster and simpler solutions in deep brain stimulation reflects its commitment to advancing therapeutic options for patients with challenging medical conditions.

Lightpoint Medical, Ltd. is a medical device company based in Rickmansworth, United Kingdom, founded in 2012. The company specializes in developing innovative imaging technologies for cancer surgery, particularly through its Cerenkov Luminescence Imaging (CLI) technology. This breakthrough intraoperative imaging tool allows for real-time detection of cancer during surgical procedures, which can significantly reduce the chances of cancer recurrence and the necessity for reoperations. By optimizing the performance of robotic cancer surgery, Lightpoint Medical aims to provide healthcare professionals with advanced tools that enhance surgical decision-making and improve patient outcomes, ultimately contributing to cost savings within the healthcare system.

Physiomics plc combines systems biology with cutting edge mathematics to develop models that streamline the drug discovery and development process. Virtual Tumour, the company’s lead service, is used to optimise the dosing and scheduling of oncology drugs in pre-clinical and clinical trials. This optimisation improves the efficacy of combinations and streamlines the drug development process.

Renephra Ltd. is a medical device company based in Manchester, United Kingdom, established in 2009. It specializes in developing innovative Transdermal Fluid Removal (TFR) technology aimed at addressing fluid overload and chronic conditions such as oedema and lymphoedema. The company's devices utilize a micro-needle system combined with negative pressure therapy to facilitate minimally invasive fluid removal from the skin. This technology targets significant clinical needs within vascular and oncology patients, representing a large and underserved market estimated at £1 billion globally. Having achieved proof of concept in human trials, Renephra is currently seeking funding to advance its device development and feasibility studies.

GripAble Ltd. designs and develops digital therapy devices aimed at improving rehabilitation for individuals with movement impairments such as stroke, arthritis, cerebral palsy, and trauma. Founded in 2017 and based in London, the company offers a portable, wireless handgrip device that connects to a mobile application. This application allows users to engage with therapy games while providing assessment and training for hand and arm functions. GripAble's innovative approach focuses on making therapy more accessible and engaging for patients, enabling them to practice essential daily tasks in a fun and motivating way. By combining hardware and software, GripAble addresses the needs of over 500 million people worldwide who face challenges with arm mobility, facilitating self-training both in clinical settings and at home.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, focused on developing point-of-care diagnostic solutions for infectious diseases. Established in 2005, the company offers the binx io system, a FDA-cleared and CLIA-waived platform that detects sexually transmitted infections, including chlamydia and gonorrhea, delivering results comparable to central lab performance within approximately thirty minutes. Additionally, Binx Health provides the Callisto system, which meets various throughput requirements for testing in decentralized and near-patient settings. The company's innovative approach aims to enhance access to healthcare by overcoming traditional barriers and improving patient experiences through rapid polymerase chain reaction (PCR)-based testing and a comprehensive digital program that includes counseling and follow-up care. Binx Health has also formed a strategic partnership with Sherlock Biosciences to further advance its capabilities in diagnostics.

SleepCogni is focused on developing innovative sleep aid technology that facilitates a personalized wind-down process to enhance sleep quality. The company's device, activated manually, utilizes sensors worn on the user's index finger to monitor key physiological and behavioral indicators, including heart rate, mental alertness, skin temperature, and movement. By employing cognitive behavioral therapy through biofeedback—delivered via visual, auditory, and tactile cues—SleepCogni aims to help users relearn healthy sleep patterns. This approach is designed to assist individuals in overcoming insomnia and improving their overall sleep cycle, offering a tailored solution to address common sleep challenges.

Jellagen is a Med-Tech company specializing in high-grade native collagen sourced from jellyfish. This unique collagen is utilized for a range of applications in tissue engineering, regenerative medicine, stem cell research, and various cell culture processes. Jellagen provides its products in both solution and powder forms, ensuring batch-to-batch consistency that is beneficial for research and medical applications. By offering non-mammalian collagen, the company enables medicinal researchers to conduct in-house research and development, supporting the creation of innovative medical devices and advancing new methods for wound management and tissue engineering.

Entia is a medical technology company that specializes in improving access to blood tests. Its featured products include Aptus, designed for haemoglobin and haematocrit and Affinity, designed for people with cancer to monitor their blood counts at home. The company is a multidisciplinary team spanning design, engineering, quality assurance, business development, and innovation.

BrainWaveBank has developed a first-in-class wearable electroencephalography (EEG) device to conveniently and non-invasively measure the mechanisms that underpin neurological disorders and therapies. Our platform can securely gather, store and analyse data from many thousands of users, building neurocognitive profiles of individuals and populations or demographic groups. This easy-to-scale and distributable approach will help clinical professionals to transform our understanding of brain health and develop the next generation of treatments. BrainWaveBank was founded in January 2015 and has offices in Belfast , Northern Ireland and Dublin, Ireland.

Sarissa Biomedical, Ltd. specializes in the development and production of innovative biosensors aimed at measuring neuroactive chemicals for research and clinical diagnostic purposes. The company focuses on creating minimally invasive, microelectrode electrochemical sensors that accurately measure purines and other neurochemicals, serving as indicators of neurological activity and disorders. These biosensors are suitable for both in vitro and in vivo studies. Additionally, Sarissa Biomedical is developing a hand-held point-of-care diagnostic device that utilizes finger-prick blood samples to identify individuals experiencing strokes. Founded in 2002 and based in Coventry, the United Kingdom, Sarissa Biomedical markets its products in various regions, including the United Kingdom, United States, Canada, and Japan.

Arterius Limited is developing a novel next-generation polymer-based Bio-resorbable Coronary Scaffold (BRS), more commonly known as a ‘stent’. The bio-resorbable attribute allows the stent to dissolve over time, typically 12–24 months, before being absorbed by the body. Therefore, there is no requirement to physically remove the stent. The Company’s solution offers a huge opportunity to minimise the frequency of surgery or medical interventions and could give patients a better post-operative quality of life.

Sky Medical Technology is a growth-stage bioelectronic medicine platform that completely redefines the way vascular related conditions are treated. The company has developed a neuromodulation therapy called OnPulse™, the first clinically proven bioelectronic compression technology to prevent and treat a wide range of acute and chronic circulatory conditions. The first indications for the OnPulse wearable therapy are life threatening blood clots, swelling after orthopedic surgery, long term non-healing wounds, as well as applications for pro athletes to speed-up recovery time between games and during travel, conditions experienced by more than forty million people currently with unmet need.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

Glyconics Ltd. is a diagnostics company based in Cambridge, United Kingdom, specializing in the development of portable infrared spectroscopy devices for the diagnosis and monitoring of chronic obstructive pulmonary disease (COPD) and other respiratory conditions. Established in 2013, the company has created a hand-held device that utilizes Fourier transform infrared spectroscopy (FTIR) to analyze sputum samples for specific biomarkers associated with COPD. This innovative technology allows patients to perform diagnoses and monitor their health from home, facilitating early detection and management of respiratory diseases. By identifying particular spectral signatures in the samples, the device supports healthcare professionals in assessing and understanding patients' conditions more effectively.

Oxehealth Ltd. is a technology company based in Oxford, United Kingdom, that specializes in non-contact vital signs monitoring solutions. Founded in 2012, the company has developed the Oxecam software, which enables the measurement of heart rate, respiratory rate, and blood oxygenation using a digital video camera. This innovative system is particularly beneficial in healthcare settings, including mental health facilities and care homes, where staff may not always be present to monitor patients. Oxehealth's technology provides alerts for potentially risky activities and offers objective data for care planning, enhancing the ability of clinicians and caregivers to support vulnerable individuals. By employing advanced algorithms that utilize deep learning and computer vision, Oxehealth aims to improve patient monitoring and management while allowing staff more time for direct care. The company has achieved world-first certification for its software as a medical device, marking a significant advancement in remote patient monitoring.

Zilico is developing the next generation of cancer diagnostics that will provide real-time diagnosis for cervical cancer and reduce the inherent subjectivity of current methods. Two applications are under development: the first for the referral market and the second for the screening market.

Lightpoint Medical, Ltd. is a medical device company based in Rickmansworth, United Kingdom, founded in 2012. The company specializes in developing innovative imaging technologies for cancer surgery, particularly through its Cerenkov Luminescence Imaging (CLI) technology. This breakthrough intraoperative imaging tool allows for real-time detection of cancer during surgical procedures, which can significantly reduce the chances of cancer recurrence and the necessity for reoperations. By optimizing the performance of robotic cancer surgery, Lightpoint Medical aims to provide healthcare professionals with advanced tools that enhance surgical decision-making and improve patient outcomes, ultimately contributing to cost savings within the healthcare system.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

Smart Surgical Appliances is a medical device company focused on developing sensor-enabled surgical instruments that enhance the safety and effectiveness of minimally invasive procedures, including keyhole surgery, endoscopic surgery, and natural orifice transluminal endoscopic surgeries. The company's innovative instruments provide real-time sensing and feedback from the operative site, similar to the tactile feedback experienced in traditional surgeries. By improving the clinical efficacy of these procedures, Smart Surgical Appliances aims to reduce costs and minimize risks associated with surgical interventions, ultimately enhancing patient outcomes and the overall surgical experience for both physicians and patients.

Isogenica Limited is a biotechnology company based in Little Chesterford, United Kingdom, that specializes in designing and licensing synthetic antibody libraries and display technologies for antibody discovery. The company offers several systems, including the llamdA System for single-domain antibodies, the Xab System for human antibody fragments, and the 4D Fab System for synthetic human antibodies. Additionally, Isogenica provides peptide and scaffold platforms to facilitate the development of therapeutic peptides aimed at treating diseases. Its proprietary vitro display technology, known as CIS display, is employed to discover biologically active peptides, proteins, and antibodies. The company's innovative small-format antibodies can be utilized to create bispecific and multi-specific biotherapeutics, enhancing targeted drug delivery in applications such as antibody-drug conjugates and cell and gene therapies. Established in 1998 and originally named Pharmacophorix Limited, Isogenica serves pharmaceutical and biotechnology sectors, contributing significantly to advancements in medical research and therapeutic development.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.